---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-008080"
form_type: "8-K"
ticker: "CSBR"
cik: "0000771856"
company_name: "CHAMPIONS ONCOLOGY, INC."
filed_at: "2023-03-15T23:59:59+00:00"
generated_at: "2026-06-18T02:36:53.837629+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Champions Oncology Q3 revenue $12.8M (-3.2% YoY), operating loss $2.5M, adj EBITDA -$1.6M

## Summary
- Revenue declined 3.2% to $12.8M from $13.2M a year ago, driven by macro-related customer cancellations.
- Operating loss of $2.5M vs income of $0.83M in prior year; adjusted EBITDA loss of $1.6M vs positive $1.5M.
- Record quarterly bookings; cash on hand $11.6M with no debt; net cash from ops $1.6M in Q3.
- R&D spend increased $1.0M (46.8%) to $3.2M, mainly for therapeutic target discovery platform.
- CEO expects improved results in fiscal 2024; YTD revenue up 12.6% to $40.8M but operating loss of $2.7M.

## SEC filing metadata
- accession: 0001628280-23-008080
- form_type: 8-K
- ticker: CSBR
- cik: 0000771856
- company_name: CHAMPIONS ONCOLOGY, INC.
- filed_at: 2023-03-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/771856/000162828023008080/0001628280-23-008080-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/771856/000162828023008080/csbr-20230315.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-008080
- JSON: https://secwatch.observer/filing/0001628280-23-008080.json
- Plain text: https://secwatch.observer/filing/0001628280-23-008080.txt

## Key facts
- Earnings Releases
  CHAMPIONS ONCOLOGY, INC. reported third quarter of fiscal 2023, ended January 31, 2023 results: revenue $12.8 million.
  - Period: third quarter of fiscal 2023, ended January 31, 2023
  - Revenue: $12.8 million
  - Result: reported results
  source text: Champions Oncology Reports Quarterly Revenue of $12.8 Million
  evidence_url: https://www.sec.gov/Archives/edgar/data/771856/000162828023008080/0001628280-23-008080-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.